Mar 28, 2008 by Brian LawlerAmgen and Roche Still Duking It OutAmgen threatens to sue Roche for damages.
Mar 28, 2008 by Brian LawlerPfizer Gets the Signal to StealThe drug company's acquisition of Encycsive Pharmaceuticals is set for Monday.
Mar 28, 2008 by Brian LawlerVertex Tantalizes Us With Very Early DataVertex announces positive early-stage data for a cystic fibrosis drug.
Mar 27, 2008 by Brian LawlerA Drugmaker's Candid Thoughts on the FDACardiome updates investors on its top two drugs.
Mar 27, 2008 by Brian LawlerA Little Bit of Cash for ArQuleArQule receives a milestone payment from a partner.
Mar 27, 2008 by Brian LawlerEli Lilly Hands Over Cold CashLilly loses to Alaska in a courtroom battle over its top drug.
Mar 26, 2008 by Brian LawlerCelgene Brings in an OrphanThe FDA grants a Celgene drug orphan designation.
Mar 26, 2008 by Brian LawlerTake Two for DepomedThe pharmaceutical starts another study for its proposed pain drug.
Mar 20, 2008 by Brian LawlerThe AIR's Knocked Out of AlkermesAlkermes initiates a round of cost-cutting.
Mar 19, 2008 by Brian LawlerRoche to Amgen: We SurrenderAt a court's urging, the pharmaceutical coughs up higher anemia-drug royalties.
Mar 19, 2008 by Brian LawlerInterMune Suffers a PostscriptThe former CEO is indicted, but that shouldn't hurt the drugmaker.
Mar 18, 2008 by Brian LawlerQLT's Blemished Aczone Clears UpA more lenient label from the FDA is good news for the drugmaker.
Mar 18, 2008 by Brian LawlerCardiome's Yin and YangCardiome reports positive mid-stage data for a drug.
Mar 17, 2008 by Brian LawlerThe Paneling on Amgen's WallsOne FDA panel ruling is a win, another is much less upsetting than investors feared.
Mar 17, 2008 by Brian LawlerParsing the Details With DendreonMore on the Dendreon clinical trial amendments.
Mar 17, 2008 by Brian LawlerGenentech Takes Center StageThere might be more partnerships in store for the drugmaker.
Mar 13, 2008 by Brian LawlerDendreon Rolls the DiceThe pharmaceutical amends a phase 3 study on its lead drug.
Mar 12, 2008 by Brian LawlerA New Wave for Third WaveThe company might be able to help women who test positive for a common STD.
